Embecta (NASDAQ:EMBC) Stock Rating Upgraded by Zacks Research

Key Points

• Zacks Research has upgraded Embecta (NASDAQ:EMBC) from a "hold" to a "strong-buy" rating, indicating confidence in the company's future performance.
• Embecta recently reported earnings of $1.12 per share for the last quarter, which surpassed analysts' expectations and represented an 8.4% year-over-year revenue increase.
• Institutional investors now hold a substantial 93.83% of Embecta's stock, reflecting strong interest and confidence from large financial entities.

Embecta (NASDAQ:EMBC - Get Free Report) was upgraded by equities researchers at Zacks Research from a "hold" rating to a "strong-buy" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other research firms have also commented on EMBC. BTIG Research set a $25.00 target price on Embecta and gave the company a "buy" rating in a report on Friday, May 23rd. Wall Street Zen raised Embecta from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Finally, Mizuho lowered their target price on Embecta from $13.00 to $12.00 and set a "neutral" rating for the company in a report on Wednesday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $19.00.

Embecta Trading Down 0.1%

NASDAQ EMBC traded down $0.02 on Tuesday, hitting $14.48. 366,799 shares of the stock traded hands, compared to its average volume of 688,264. The stock has a 50-day moving average of $11.41 and a 200 day moving average of $11.87. Embecta has a twelve month low of $9.20 and a twelve month high of $21.48. The company has a market capitalization of $846.94 million, a P/E ratio of 10.13, a price-to-earnings-growth ratio of 0.80 and a beta of 1.11.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.35. Embecta had a negative return on equity of 23.40% and a net margin of 7.58%.The firm had revenue of $295.50 million for the quarter, compared to analysts' expectations of $278.15 million. During the same quarter in the prior year, the firm posted $0.74 earnings per share. Embecta's revenue for the quarter was up 8.4% compared to the same quarter last year. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. As a group, equities research analysts expect that Embecta will post 2.85 earnings per share for the current year.

Hedge Funds Weigh In On Embecta

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC boosted its stake in Embecta by 103.6% during the 2nd quarter. Squarepoint Ops LLC now owns 403,412 shares of the company's stock valued at $3,909,000 after purchasing an additional 205,311 shares in the last quarter. Public Sector Pension Investment Board boosted its stake in Embecta by 8.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 199,227 shares of the company's stock valued at $1,931,000 after purchasing an additional 14,908 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Embecta by 542.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company's stock valued at $71,000 after purchasing an additional 6,224 shares in the last quarter. Man Group plc boosted its stake in Embecta by 25.6% during the 2nd quarter. Man Group plc now owns 36,002 shares of the company's stock valued at $349,000 after purchasing an additional 7,339 shares in the last quarter. Finally, Humankind Investments LLC bought a new position in Embecta during the 2nd quarter valued at $111,000. 93.83% of the stock is owned by institutional investors.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.